In addition, our data suggest that the usage of compounds that directly or indirectly activate AMPK in other pathologies such as diabetes, mitochondrial disease and cardiovascular diseases57, might need to be carefully evaluated, particularly in those patients with advanced cancer. This evidence concerns the gene PRKAA1 and mitochondrial disease.